Alogliptin
Encyclopedia
Alogliptin is an investigational anti-diabetic drug
in the DPP-4 inhibitor class, being developed by Takeda Pharmaceutical Company
. In January 2008, Takeda submitted a New Drug Application
for alogliptin to the U.S. Food and Drug Administration
, after positive results from Phase III clinical trial
s. However, the FDA submission was suspended or withdrawn in June 2009 needing more data.
Anti-diabetic drug
Anti-diabetic medications treat diabetes mellitus by lowering glucose levels in the blood. With the exceptions of insulin, exenatide, and pramlintide, all are administered orally and are thus also called oral hypoglycemic agents or oral antihyperglycemic agents...
in the DPP-4 inhibitor class, being developed by Takeda Pharmaceutical Company
Takeda Pharmaceutical Company
is the largest pharmaceutical company in Japan and Asia and a top 15 pharmaceutical company. The company has over 19,000 employees worldwide and achieved $15.7 billion USD in revenue during the 2008 fiscal year...
. In January 2008, Takeda submitted a New Drug Application
New drug application
The New Drug Application is the vehicle in the United States through which drug sponsors formally propose that the Food and Drug Administration approve a new pharmaceutical for sale and marketing...
for alogliptin to the U.S. Food and Drug Administration
Food and Drug Administration
The Food and Drug Administration is an agency of the United States Department of Health and Human Services, one of the United States federal executive departments...
, after positive results from Phase III clinical trial
Clinical trial
Clinical trials are a set of procedures in medical research and drug development that are conducted to allow safety and efficacy data to be collected for health interventions...
s. However, the FDA submission was suspended or withdrawn in June 2009 needing more data.